



Design and Computational Evaluation of Novel Bioactive Compounds Using Molecular Docking and ADMET Analysis

Dr. Iwan de Esch

Professor

Department of Medicinal Chemistry

Leiden University

Abstract

The discovery of biologically active compounds is a complex and resource-intensive process requiring extensive experimental investigation to identify molecules with desirable potency, selectivity, pharmacokinetic behaviour and safety characteristics. Computational drug-discovery techniques provide an opportunity to accelerate early-stage compound screening by prioritising promising candidates before experimental synthesis and biological evaluation. This paper presents a computational framework for the design and evaluation of novel bioactive compounds using molecular docking and absorption, distribution, metabolism, excretion and toxicity (ADMET) analysis. The proposed approach integrates molecular structure design, physicochemical-property assessment, molecular docking, interaction analysis and pharmacokinetic prediction into a sequential computational workflow. Molecular docking is employed to estimate ligand–target binding modes and identify important interactions within the active site, while ADMET analysis is used to evaluate drug-likeness and potential pharmacokinetic and toxicity liabilities. The framework emphasises the importance of combining docking scores with interaction profiles and ADMET characteristics rather than relying on a single computational indicator. A multi-parameter prioritisation strategy is proposed for ranking candidate molecules according to predicted binding affinity, interaction quality, physicochemical properties and safety-related characteristics. The study further discusses limitations associated with docking accuracy, protein flexibility, scoring functions, prediction uncertainty and the need for experimental validation. The integrated methodology provides a systematic and cost-effective strategy for narrowing large chemical libraries to a smaller set of experimentally tractable candidates. Such computational approaches can contribute to more efficient early-stage drug discovery and support the rational design of novel bioactive compounds.

Keywords: Bioactive Compounds, Molecular Docking, ADMET, Computational Drug Discovery, Virtual Screening, Drug Design, Pharmacokinetics, Toxicity Prediction, Ligand–Protein Interaction, Drug-Likeness.


1. Introduction

The discovery of novel bioactive compounds is an important component of pharmaceutical research. Conventional drug discovery involves extensive laboratory screening, synthesis, optimisation and biological testing.

The process can be expensive because a large proportion of candidate compounds fail during later stages of development.

Computational drug-discovery approaches can reduce this burden by allowing researchers to evaluate chemical structures before committing substantial laboratory resources.

A typical computational workflow involves:



Molecular docking provides information about how a candidate ligand may interact with a biological target, while ADMET analysis provides complementary information regarding pharmacokinetic and toxicity characteristics.

2. Computational Drug Discovery

Computational drug discovery uses mathematical and computational methods to investigate:

- Molecular structure.

- Protein–ligand interactions.
- Binding affinity.
- Molecular properties.
- Pharmacokinetics.
- Toxicity.
- Chemical similarity.

Its primary advantage is the ability to screen large numbers of molecules relatively quickly.

3. Rational Design of Bioactive Compounds

Rational compound design begins with identifying a biological target associated with a disease or physiological process.

The target may be:

- Enzyme.
- Receptor.
- Ion channel.
- Transporter.
- Protein–protein interaction site.

Once a suitable target is selected, computational methods can be used to identify molecules capable of interacting with it.

4. Target Selection

Target selection is critical because the quality of the computational prediction depends strongly on the quality of the target structure.

Important considerations include:

- Biological relevance.
- Availability of structural information.
- Resolution of the protein structure.
- Presence of a well-defined binding site.
- Availability of experimentally characterised ligands.

Protein structures may be obtained from experimentally determined structural databases or reliable computational models.

5. Ligand Design

Novel ligands can be generated through:

- Scaffold modification.

- Functional-group substitution.
- Fragment-based design.
- Analogue design.
- Structure-based optimisation.
- Virtual compound generation.

The objective is to modify molecular structures while maintaining or improving biological activity.

6. Molecular Representation

Before computational analysis, compounds need to be represented in suitable molecular formats.

Important structural information includes:


- Atomic coordinates.
- Bond connectivity.
- Bond orders.
- Formal charges.
- Hydrogen atoms.
- Stereochemistry.

Incorrect structure preparation can produce misleading docking results.

7. Molecular Docking

Molecular docking predicts how a ligand may fit into a target-binding site.

The process generally involves:



8. Protein Preparation

Protein preparation may involve:

- Removing inappropriate molecules.
- Adding missing hydrogen atoms.
- Assigning protonation states.
- Correcting structural issues.
- Defining relevant cofactors.

The objective is to generate a chemically meaningful computational representation of the target.

9. Binding-Site Identification

The binding site can be identified using:

- Known ligand coordinates.
- Experimental structural information.
- Conserved active-site residues.
- Computational pocket-detection methods.

Accurate binding-site definition is important for meaningful docking.

10. Ligand Preparation

Ligand preparation may include:

- Geometry optimisation.
- Hydrogen addition.
- Charge assignment.
- Tautomer identification.
- Protonation-state assessment.
- Stereochemical verification.

Different protonation or tautomeric states may influence predicted interactions.

11. Docking Pose Generation

Docking algorithms generate multiple possible orientations of a ligand inside the binding site.

These are commonly referred to as binding poses.

The algorithm attempts to identify geometrically and energetically favourable configurations.

12. Docking Scoring

Docking programs generally use scoring functions to estimate the favourability of predicted ligand–target interactions.

Factors may include:

- Hydrogen bonding.
- Hydrophobic interactions.
- Electrostatic interactions.
- Van der Waals interactions.
- Solvation effects.

Docking scores should be interpreted as computational estimates rather than direct measurements of experimental binding affinity.

13. Protein–Ligand Interactions

Important interactions can include:

Hydrogen Bonds

Directional interactions between suitable donor and acceptor groups.

Hydrophobic Interactions

Interactions involving non-polar molecular surfaces.

π – π Interactions

Interactions between aromatic systems.

Electrostatic Interactions

Attractive or repulsive interactions involving charged groups.

Halogen Bonding

Directional interactions that can sometimes contribute to ligand recognition.

14. Binding-Pose Analysis

A high docking score alone does not necessarily indicate a strong candidate.

The predicted pose should also be examined for:

- Correct orientation.
- Interaction with important residues.
- Appropriate occupancy of the binding pocket.
- Absence of severe steric clashes.

Visual inspection and interaction analysis are therefore essential.

15. Active-Site Residue Analysis

Residues participating in ligand recognition can provide information about potential activity.

For example, a candidate may form favourable interactions with residues known to be important for:

- Catalysis.
- Substrate recognition.
- Inhibitor binding.

Such observations can strengthen the rationale for further investigation.

16. Virtual Screening

Molecular docking can be applied to large compound libraries.

A virtual-screening workflow can be represented as:

Chemical Library



Pre-filtering



Docking



Pose Evaluation



Ranking



ADMET Filtering



Lead Candidates

This can substantially reduce the number of molecules requiring experimental testing.

17. ADMET Analysis

ADMET refers to:

- **Absorption**
- **Distribution**
- **Metabolism**
- **Excretion**
- **Toxicity**

A compound with strong predicted target binding may still fail because of poor pharmacokinetic or safety characteristics.

Therefore, docking and ADMET analysis should be considered complementary.

18. Absorption

Absorption describes how a compound enters systemic circulation.

Important factors include:

- Molecular size.
- Lipophilicity.
- Polarity.
- Hydrogen-bonding capacity.
- Ionisation.

Poor absorption can limit the usefulness of an otherwise promising molecule.

19. Distribution

Distribution describes how a compound moves through biological compartments.

Computational analysis may consider:

- Plasma-protein binding.
- Tissue distribution.
- Lipophilicity.
- Membrane permeability.

Distribution characteristics can influence both efficacy and toxicity.

20. Metabolism

Metabolism can transform drug molecules into:

- Active metabolites.
- Inactive metabolites.
- Potentially toxic metabolites.

Computational prediction can help identify possible metabolic liabilities at an early stage.

21. Excretion

Excretion determines how compounds and their metabolites are removed from the body.

Important factors include:

- Renal clearance.
- Hepatic elimination.
- Molecular properties.

Poor clearance may cause excessive exposure.

22. Toxicity

Toxicity prediction is an important component of early compound evaluation.

Potential computational endpoints include:

- Hepatotoxicity.
- Cardiotoxicity.
- Mutagenicity.
- Cytotoxicity.
- Acute toxicity.

Predictions should be treated as prioritisation tools rather than definitive toxicological evidence.

23. Drug-Likeness

Drug-likeness assessment commonly considers:

- Molecular weight.
- Lipophilicity.
- Hydrogen-bond donors.
- Hydrogen-bond acceptors.
- Polar surface area.
- Rotatable bonds.

These characteristics can provide an initial indication of whether a compound possesses broadly favourable properties for further development.

24. Lipinski-Type Evaluation

Rule-based drug-likeness filters can identify compounds with physicochemical characteristics commonly associated with orally active small molecules.

However, such rules are guidelines rather than absolute exclusion criteria.

Some successful drugs fall outside conventional thresholds.

25. Physicochemical Properties


A computational compound profile may include:

Property	Importance
Molecular weight	Influences permeability and distribution
LogP/logD	Indicates lipophilicity
TPSA	Relates to polarity
H-bond donors	Influences interactions and permeability

Property	Importance
H-bond acceptors	Influences interactions
Rotatable bonds	Relates to flexibility
Solubility	Influences formulation and exposure
Ionisation	Influences distribution and absorption

26. Integrated Docking–ADMET Strategy

A more reliable computational workflow is:



This avoids selecting molecules solely because of favourable docking scores.

27. Multi-Parameter Optimisation

Candidate molecules can be evaluated according to several criteria:

Criterion	Desired Outcome
Docking score	Favourable
Binding interactions	Strong and plausible

Criterion	Desired Outcome
Drug-likeness	Acceptable
Solubility	Adequate
Absorption	Favourable
Metabolism	Manageable
Toxicity	Low predicted risk
Synthetic accessibility	Practical

28. Candidate Ranking

A conceptual prioritisation score could combine:

Binding Performance + Molecular Properties + ADMET Profile + Synthetic Feasibility

The purpose is to identify molecules that have a balanced profile rather than an extreme value for one parameter.

29. Computational Workflow

Step 1: Target Identification

Select a biologically relevant protein.

Step 2: Protein Structure Preparation

Prepare and validate the target structure.

Step 3: Ligand Design

Generate novel candidate molecules.

Step 4: Molecular Optimisation

Optimise molecular geometries.

Step 5: Docking

Generate and rank binding poses.

Step 6: Interaction Analysis

Identify key ligand–protein interactions.

Step 7: ADMET Prediction

Evaluate pharmacokinetic and toxicity characteristics.

Step 8: Candidate Prioritisation

Select compounds with balanced computational profiles.

Step 9: Experimental Validation

Confirm predictions through laboratory studies.

30. Computational Tools

Different stages can use different computational platforms.

Task	Computational Approach
Molecular construction	Molecular modelling software
Protein preparation	Structure-preparation tools
Docking	Molecular docking platforms
Interaction analysis	Molecular visualisation tools
ADMET	Predictive ADMET platforms
Property calculation	Cheminformatics tools
Data analysis	Statistical/programming environments

The specific tool should be selected according to the target, ligand class and research objective.

31. Receptor Flexibility

One limitation of conventional docking is that proteins are often treated as relatively rigid structures.

Real proteins can undergo:

- Side-chain rearrangement.
- Loop movement.
- Domain motion.
- Conformational changes.

This can influence ligand binding.

32. Ensemble Docking

One approach for addressing protein flexibility is to dock compounds against multiple protein conformations.

This may provide a more comprehensive assessment than using a single static structure.

33. Molecular Dynamics

Molecular dynamics simulations can provide additional information regarding:

- Stability of ligand binding.
- Protein flexibility.
- Interaction persistence.
- Conformational behaviour.

Molecular docking can therefore serve as an initial screening stage, followed by more computationally intensive analyses for selected candidates.

34. Binding Stability

A ligand that produces a favourable docking pose may not necessarily remain stable during dynamic simulation.

Trajectory analysis can investigate whether key interactions persist over time.

35. Machine Learning Integration

Machine learning can complement docking and ADMET analysis.

Potential applications include:

- Activity prediction.
- Property prediction.
- Toxicity prediction.
- Virtual screening.
- Compound prioritisation.

An integrated pipeline could combine:

Docking + Molecular Descriptors + ML + ADMET

36. Generative Molecular Design

Generative AI can propose new molecular structures based on:


- Desired target interactions.
- Molecular-property constraints.
- Chemical scaffolds.
- Drug-likeness criteria.

Generated compounds can subsequently undergo docking and ADMET filtering.

37. Structure–Activity Relationships

Computational analysis can help identify relationships between molecular modifications and predicted activity.

For example:



This supports rational lead development.

38. Lead Optimisation

Once promising scaffolds are identified, structural modifications can be introduced to improve:

- Binding.
- Selectivity.
- Solubility.
- Stability.
- Pharmacokinetics.

The objective is to optimise the complete molecular profile rather than binding affinity alone.

39. Selectivity

A compound with strong binding to its intended target may still interact with unrelated proteins.

Therefore, future computational workflows should consider:

- Off-target docking.
- Similarity-based prediction.
- Selectivity profiling.

This may help identify potential safety concerns.

40. Synthetic Feasibility

Computationally promising compounds may be difficult to synthesise.

Candidate prioritisation should therefore consider:

- Number of synthetic steps.
- Availability of starting materials.

- Reaction complexity.
- Chemical stability.

Synthetic feasibility is an important bridge between computational discovery and laboratory validation.

41. Proposed Computational Framework

The proposed framework consists of six layers:

Layer 1 — Molecular Design

Generate candidate bioactive compounds.

Layer 2 — Molecular Property Assessment

Calculate physicochemical and drug-likeness parameters.

Layer 3 — Molecular Docking

Predict target-binding modes.

Layer 4 — Interaction Analysis

Assess binding-site interactions.


Layer 5 — ADMET Assessment


Predict pharmacokinetic and toxicity characteristics.

Layer 6 — Candidate Prioritisation

Select compounds for experimental evaluation.

42. Conceptual Architecture





43. Evaluation Metrics

Important computational metrics include:

Metric	Purpose
Docking score	Estimate binding favourability
RMSD	Assess pose similarity where appropriate
Interaction count	Characterise binding
H-bond interactions	Evaluate specific recognition
LogP/logD	Assess lipophilicity
TPSA	Assess polarity
Solubility	Evaluate formulation potential
Predicted absorption	Assess pharmacokinetic potential
Predicted toxicity	Identify safety liabilities

44. Statistical and Comparative Analysis

Candidate compounds can be compared systematically.

For example, compounds can be classified into:

- High docking / favourable ADMET.
- High docking / unfavourable ADMET.
- Moderate docking / favourable ADMET.
- Low docking / unfavourable ADMET.

The first category would generally represent the highest-priority candidates, subject to further validation.

45. Advantages of the Integrated Approach

The proposed approach can:

1. Reduce experimental screening requirements.
2. Prioritise promising compounds.
3. Identify potential liabilities early.
4. Support rational structural optimisation.
5. Integrate multiple molecular properties.
6. Improve research efficiency.
7. Reduce the cost of early-stage screening.

46. Limitations

Computational predictions have several limitations.

Docking limitations

- Simplified scoring functions.
- Limited treatment of protein flexibility.
- Solvation approximations.
- Dependence on protein structure quality.

ADMET limitations


- Prediction uncertainty.
- Dataset bias.
- Limited biological complexity.
- Differences between computational predictions and clinical behaviour.

Therefore, computational findings require experimental validation.

47. Experimental Validation

The computational pipeline should ultimately lead to laboratory testing.

Potential validation stages include:



↓
Cell-Based Testing

↓
Preclinical Evaluation

The exact pathway depends on the intended application and development stage.

48. Research Questions

1. How effectively can molecular docking prioritise novel bioactive compounds?
2. How does ADMET prediction influence computational lead selection?
3. Which molecular descriptors are most strongly associated with favourable candidate profiles?
4. Can multi-parameter optimisation improve candidate prioritisation compared with docking alone?
5. How can protein flexibility be incorporated into computational screening?
6. Can machine learning improve binding and ADMET prediction?
7. How can generative molecular design accelerate lead optimisation?
8. How can computational predictions be experimentally validated?
9. What factors contribute most strongly to false-positive docking predictions?
10. How can computational workflows improve the efficiency of early-stage drug discovery?

49. Future Research Directions

Future work can integrate:

- Molecular docking.
- Molecular dynamics.
- Free-energy calculations.
- Machine learning.
- Generative AI.
- Multi-target screening.
- Toxicity prediction.
- Synthetic-accessibility prediction.
- Automated compound design.

The long-term objective is a closed-loop computational–experimental discovery platform.

50. Discussion

Molecular docking and ADMET analysis provide complementary perspectives on candidate quality.

Docking primarily addresses:

Can the molecule plausibly interact with the target?

ADMET analysis addresses:

Could the molecule possess suitable pharmacokinetic and safety characteristics?

Neither question is sufficient independently.

A molecule may show excellent predicted target binding but poor absorption, excessive toxicity or undesirable metabolism.

Conversely, a compound may have excellent pharmacokinetic characteristics but insufficient target interaction.

Therefore, successful computational drug discovery requires balanced optimisation.

51. Importance of Experimental Confirmation

Computational models should be considered hypothesis-generation tools.

A favourable computational profile does not establish:

- Biological activity.
- Clinical efficacy.
- Safety.
- Therapeutic effectiveness.

Experimental testing remains essential.

52. Conclusion

The design and computational evaluation of novel bioactive compounds using molecular docking and ADMET analysis provide a systematic approach for accelerating early-stage drug discovery. Molecular docking can help identify plausible ligand–target binding modes and prioritise compounds according to predicted interaction characteristics, while ADMET analysis can identify potential pharmacokinetic and toxicity liabilities before substantial experimental resources are invested.

The integrated workflow proposed in this paper combines molecular design, physicochemical-property assessment, docking, binding-interaction analysis, ADMET prediction and multi-parameter candidate prioritisation. This approach is more informative than relying on docking scores alone because drug-development success depends on a

combination of target activity, molecular properties, pharmacokinetics, safety and practical synthetic feasibility.

Future computational platforms are likely to increasingly integrate molecular dynamics, machine learning, generative molecular design and automated experimentation. Such integration could create iterative systems in which computational models generate candidate molecules, experimental data are continuously incorporated and subsequent molecular designs are refined accordingly.

Nevertheless, computational predictions remain subject to uncertainties arising from protein flexibility, scoring functions, incomplete datasets and the complexity of biological systems. Therefore, computationally identified candidates must ultimately undergo appropriate experimental validation.

Overall, the combination of molecular docking and ADMET analysis represents a valuable decision-support framework for rational bioactive-compound discovery, enabling researchers to narrow chemical space, identify promising molecular scaffolds and focus experimental resources on candidates with more balanced predicted profiles.

References

1. Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. *Nature Reviews Drug Discovery*, 3, 935–949.
2. Meng, X.-Y., Zhang, H.-X., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. *Current Computer-Aided Drug Design*, 7(2), 146–157.
3. Morris, G. M., Huey, R., Lindstrom, W., et al. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *Journal of Computational Chemistry*, 30(16), 2785–2791.
4. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimisation and multithreading. *Journal of Computational Chemistry*, 31(2), 455–461.
5. Ferreira, L. G., Dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. *Molecules*, 20(7), 13384–13421.

6. Lionta, E., Spyrou, G., Vassilatis, D., & Cournia, Z. (2014). Structure-based virtual screening for drug discovery: Principles, applications and recent advances. *Current Topics in Medicinal Chemistry*, 14(16), 1923–1938.
7. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*, 46(1–3), 3–26.
8. Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. *Journal of Medicinal Chemistry*, 45(12), 2615–2623.
9. Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*, 7, 42717.
10. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. *Journal of Medicinal Chemistry*, 58(9), 4066–4072.
11. van de Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise? *Nature Reviews Drug Discovery*, 2, 192–204.
12. Ekins, S., Puhl, A. C., Zorn, K. M., et al. (2019). Exploiting machine learning for end-to-end drug discovery and development. *Nature Materials*, 18, 435–441.
13. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery*, 18, 463–477.
14. Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014). Computational methods in drug discovery. *Pharmacological Reviews*, 66(1), 334–395.
15. Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015). Role of computer-aided drug design in modern drug discovery. *Archives of Pharmacal Research*, 38, 1686–1701.